News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
6,566 Results
Type
Article (781)
Press Release (5786)
Section
Business (2137)
Career Advice (5)
Deals (406)
Drug Delivery (4)
Drug Development (703)
Employer Resources (1)
FDA (264)
Job Trends (168)
News (3668)
Policy (823)
Tag
Academia (10)
Alliances (365)
Alzheimer's disease (2)
Approvals (268)
Artificial intelligence (6)
Autoimmune disease (2)
Bankruptcy (8)
Best Places to Work (71)
Biosimilars (61)
BioSpace Insights (5)
Cancer (1)
Career advice (4)
CDMO (3)
Celiac Disease (1)
Cell therapy (1)
Clinical research (631)
Collaboration (11)
Complete response letters (2)
COVID-19 (18)
C-suite (17)
Data (35)
Denatured (3)
Diabetes (1)
Diagnostics (7)
Digital health (1)
Diversity, equity & inclusion (1)
Drug pricing (11)
Drug shortages (1)
Duchenne muscular dystrophy (2)
Earnings (705)
Editorial (1)
Employer resources (1)
Events (527)
Executive appointments (12)
FDA (292)
Funding (8)
Gene therapy (1)
GLP-1 (11)
Government (99)
Guidances (4)
Healthcare (69)
Huntington's disease (1)
Immunology and inflammation (6)
Indications (2)
Infectious disease (18)
Inflammatory bowel disease (14)
Inflation Reduction Act (1)
Intellectual property (1)
IPO (84)
IRA (3)
Job creations (88)
Job search strategy (4)
JPM (2)
Labor market (7)
Layoffs (27)
Legal (456)
Manufacturing (6)
MASH (2)
Medical device (21)
Medtech (21)
Mergers & acquisitions (330)
Metabolic disorders (7)
mRNA (2)
Multiple sclerosis (5)
Neurodegenerative disease (1)
Neuropsychiatric disorders (2)
Neuroscience (31)
NextGen: Class of 2026 (42)
Non-profit (8)
Now hiring (1)
Obesity (4)
Opinion (8)
Patents (5)
People (724)
Pharmacy benefit managers (2)
Phase 1 (79)
Phase 2 (192)
Phase 3 (352)
Pipeline (69)
Policy (6)
Postmarket research (69)
Preclinical (30)
Prostate cancer (1)
Radiopharmaceuticals (1)
Rare diseases (3)
Real estate (31)
Regulatory (325)
Reports (1)
Research institute (9)
RNA editing (2)
Schizophrenia (15)
Series A (2)
Special edition (1)
Startups (28)
Supply chain (2)
Vaccines (2)
Weight loss (3)
Women's health (1)
Date
Today (1)
Last 7 days (4)
Last 30 days (21)
Last 365 days (146)
2026 (112)
2025 (160)
2024 (265)
2023 (240)
2022 (815)
2021 (584)
2020 (462)
2019 (329)
2018 (328)
2017 (378)
2016 (330)
2015 (516)
2014 (310)
2013 (280)
2012 (259)
2011 (251)
2010 (217)
Location
Africa (13)
Arizona (1)
Asia (1789)
Australia (59)
California (45)
Canada (9)
China (2)
Connecticut (3)
Delaware (1)
Europe (1104)
Florida (11)
Illinois (7)
Indiana (2)
Japan (2)
Maryland (1)
Massachusetts (25)
Minnesota (2)
Missouri (1)
New Jersey (66)
New York (8)
North Carolina (2)
Northern California (25)
Ohio (1)
Pennsylvania (4)
Puerto Rico (1)
Rhode Island (2)
South America (12)
South Carolina (1)
Southern California (16)
Texas (2)
United States (165)
Utah (2)
Washington D.C. (4)
Washington State (3)
Wisconsin (1)
6,566 Results for "teva".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Teva Releases Q3 2026 Aide Memoire
September 23, 2026
·
2 min read
Bankruptcy
BioXcel files for bankruptcy, plans to sell assets to Teva for up to $125M
Teva Pharmaceuticals is the ‘stalking horse bidder’ to kick off the auction process for BioXcel Therapeutics’ AI-derived assets as the biotech files for Chapter 11 bankruptcy.
August 28, 2026
·
2 min read
·
Michael Gibney
Press Releases
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
September 10, 2026
·
10 min read
Press Releases
Teva Announces Launch of Offering of Senior Notes - September 7, 2026
September 7, 2026
·
9 min read
Press Releases
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
September 28, 2026
·
12 min read
Press Releases
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September 2026
September 1, 2026
·
3 min read
Press Releases
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
September 23, 2026
·
3 min read
Press Releases
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
September 14, 2026
·
4 min read
Press Releases
Teva Releases Q2 2026 Aide Memoire
June 19, 2026
·
2 min read
Press Releases
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
August 19, 2026
·
8 min read
1 of 657
Next
